CoChat

Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries

Open access
Ullmann, A. J., Sanz, M. A., Tramarin, A., Barnes, R. A., Wu, W., Gerlach, B. A., Krobot, K. J., Gerth, W. C., on behalf of the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators · 2006 · Clinical Infectious Diseases
Cited by 115

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity. METHODS: The present prospective study collected data on outcomes for 418 adult patients treated consecutively with polyenes in hematology and oncology wards in 20 hospitals in Europe. RESULTS: Patients initially received amphotericin B deoxycholate (62% of patients), liposomal amphotericin B (27%), or other lipid formulations of amphotericin B (11%). Of the patients initially treated with amphotericin B deoxycholate, 36% had therapy switched to lipid formulations of amphotericin B, primarily because of increased serum creatinine levels (in 45.7% of patients) or other amphotericin B-attributable adverse events (in 41.3% of patients). Nephrotoxicity, which was defined as a > or = 50% increase in the serum creatinine level, developed in 57% of patients with normal kidney function at baseline. Predictors of nephrotoxicity included formulation type and duration of treatment. Compared with patients without nephrotoxicity, patients with nephrotoxicity had a higher mortality rate (24%), and their mean length of stay in the hospital was prolonged by 8.6 days. Slight increases in the serum creatinine level (i.e., > or = 50%) were associated with a significantly longer stay in the hospital. Severe nephrotoxicity (i.e., a > or = 200% increase in the serum creatinine level) was a significant predictor of death, as were severe underlying medical conditions and documented fungal infection. CONCLUSION: This prospective study confirmed that, in European hospitals, amphotericin B formulations have a major influence on the length of stay in the hospital and nephrotoxicity-associated mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/505969

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 115

Metadata

Authors
Ullmann, A. J., Sanz, M. A., Tramarin, A., Barnes, R. A., Wu, W., Gerlach, B. A., Krobot, K. J., Gerth, W. C., & on behalf of the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators
Venue
Clinical Infectious Diseases
Published
2006-08-15
Volume
43
Issue
4
Pages
e29-e38
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2143599299
Cited by
115
References
3
FWCI
7.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. https://app.cochat.ai/papers/10.1086/505969
The paper
Ullmann, A. J., Sanz, M. A., Tramarin, A., Barnes, R. A., Wu, W., Gerlach, B. A., Krobot, K. J., Gerth, W. C., & on behalf of the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. (2006). Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Clinical Infectious Diseases. https://doi.org/10.1086/505969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.